Published in Biomed Res Int on March 13, 2014
Low-temperature plasma treatment induces DNA damage leading to necrotic cell death in primary prostate epithelial cells. Br J Cancer (2015) 1.07
Low temperature plasmas as emerging cancer therapeutics: the state of play and thoughts for the future. Tumour Biol (2016) 0.78
Clinical and Biological Principles of Cold Atmospheric Plasma Application in Skin Cancer. Adv Ther (2016) 0.77
Aqueous Plasma Pharmacy: Preparation Methods, Chemistry, and Therapeutic Applications. Plasma Med (2016) 0.75
[Focal therapy for prostate cancer: German version]. Urologe A (2015) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J Exp Med (1989) 7.72
Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA (2000) 6.37
Oxidative stress: oxidants and antioxidants. Exp Physiol (1997) 6.12
Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol (2012) 6.09
Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA (2012) 5.90
Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J (1996) 5.14
The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol (2004) 4.95
Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol (2012) 4.48
Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys (1999) 4.27
The role of apoptosis in response to photodynamic therapy: what, where, why, and how. Photochem Photobiol Sci (2002) 3.23
Imaging prostate cancer: a multidisciplinary perspective. Radiology (2007) 2.79
Low-temperature sterilization using gas plasmas: a review of the experiments and an analysis of the inactivation mechanisms. Int J Pharm (2001) 2.53
Cold plasma selectivity and the possibility of a paradigm shift in cancer therapy. Br J Cancer (2011) 2.39
ROS implication in a new antitumor strategy based on non-thermal plasma. Int J Cancer (2011) 2.20
The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol (2005) 2.18
Photodynamic therapeutics: basic principles and clinical applications. Drug Discov Today (1999) 2.05
Anterior perirectal fat tissue thickness is a strong predictor of recurrence after high-intensity focused ultrasound for prostate cancer. Int J Urol (2010) 2.03
Irreversible electroporation: implications for prostate ablation. Technol Cancer Res Treat (2007) 2.01
Biochemistry of DNA lesions. Radiat Res Suppl (1985) 2.00
The role of focal therapy in the management of localised prostate cancer: a systematic review. Eur Urol (2013) 1.84
Successful and safe use of 2 min cold atmospheric argon plasma in chronic wounds: results of a randomized controlled trial. Br J Dermatol (2012) 1.78
Imaging techniques for prostate cancer: implications for focal therapy. Nat Rev Urol (2009) 1.76
Intrafractional motion of the prostate during hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys (2008) 1.73
Effect of high-intensity focused ultrasound on human prostate cancer in vivo. Cancer Res (1995) 1.65
Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. BJU Int (2012) 1.62
Targeting the cancer cell cycle by cold atmospheric plasma. Sci Rep (2012) 1.61
Endothelial cell proliferation is enhanced by low dose non-thermal plasma through fibroblast growth factor-2 release. Ann Biomed Eng (2009) 1.57
Role of nitric oxide, nitroxidative and oxidative stress in wound healing. Pharmacol Rep (2005) 1.54
Retracted Non-thermal plasma induces apoptosis in melanoma cells via production of intracellular reactive oxygen species. Ann Biomed Eng (2010) 1.54
Hypoechoic fat: a sonographic pitfall. AJR Am J Roentgenol (1995) 1.48
Role of nitric oxide in wound repair. Am J Surg (2002) 1.46
A first prospective randomized controlled trial to decrease bacterial load using cold atmospheric argon plasma on chronic wounds in patients. Br J Dermatol (2010) 1.45
The status of high-intensity focused ultrasound in the treatment of localized prostate cancer and the impact of a combined resection. Curr Urol Rep (2003) 1.44
Cold atmospheric plasma for selectively ablating metastatic breast cancer cells. PLoS One (2013) 1.41
Recent trends in prostate cancer incidence by age, cancer stage, and grade, the United States, 2001-2007. Prostate Cancer (2012) 1.38
Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol (2006) 1.38
MR imaging-guided focal laser ablation for prostate cancer: phase I trial. Radiology (2013) 1.38
Targeted photodynamic therapy via receptor mediated delivery systems. Adv Drug Deliv Rev (2004) 1.37
High intensity focused ultrasound ablation: a new therapeutic option for solid tumors. J Cancer Res Ther (2011) 1.36
Apoptosis of lung carcinoma cells induced by a flexible optical fiber-based cold microplasma. Biosens Bioelectron (2011) 1.31
Cold atmospheric plasma for the ablative treatment of neuroblastoma. J Pediatr Surg (2013) 1.27
Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. Rev Urol (2004) 1.27
Effects of a non thermal plasma treatment alone or in combination with gemcitabine in a MIA PaCa2-luc orthotopic pancreatic carcinoma model. PLoS One (2012) 1.26
High-dose intensity-modulated radiotherapy for prostate cancer using daily fiducial marker-based position verification: acute and late toxicity in 331 patients. Radiat Oncol (2008) 1.25
Real-time magnetic resonance-guided high-intensity focused ultrasound focal therapy for localised prostate cancer: preliminary experience. Eur Urol (2012) 1.23
Plasma medicine: possible applications in dermatology. J Dtsch Dermatol Ges (2010) 1.21
Skin decontamination by low-temperature atmospheric pressure plasma jet and dielectric barrier discharge plasma. J Hosp Infect (2012) 1.19
Effects of atmospheric nonthermal plasma on invasion of colorectal cancer cells. Appl Phys Lett (2010) 1.19
Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995. Int J Radiat Oncol Biol Phys (2005) 1.17
Evidence for a general relationship between the induced level of DNA double-strand breakage and cell-killing after X-irradiation of mammalian cells. Int J Radiat Biol Relat Stud Phys Chem Med (1986) 1.16
Transurethral resection (TUR) in saline plasma vaporization of the prostate vs standard TUR of the prostate: 'the better choice' in benign prostatic hyperplasia? BJU Int (2010) 1.15
Atmospheric cold plasma inactivation of Escherichia coli in liquid media inside a sealed package. J Appl Microbiol (2013) 1.14
Contrast-enhanced ultrasound imaging of prostate cancer. Rev Urol (2006) 1.13
Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation. Health Technol Assess (2010) 1.13
Efficacy and safety of bipolar plasma vaporization of the prostate with "button-type" electrode compared with transurethral resection of prostate for benign prostatic hyperplasia. Chin Med J (Engl) (2012) 1.13
High-intensity focused ultrasound (HIFU) for definitive treatment of prostate cancer. BJU Int (2012) 1.10
Focal therapy with high-intensity focused ultrasound for prostate cancer in the elderly. A feasibility study with 10 years follow-up. Int Braz J Urol (2011) 1.10
Stereotactic body radiation therapy for the primary treatment of localized prostate cancer. J Radiat Oncol (2012) 1.10
Targeted photodynamic therapy for prostate cancer: inducing apoptosis via activation of the caspase-8/-3 cascade pathway. Int J Oncol (2010) 1.09
Toxic and signaling effects of photochemically or chemically generated singlet oxygen in biological systems. Biol Chem (1997) 1.09
Proton beam therapy and localised prostate cancer: current status and controversies. Br J Cancer (2013) 1.08
Active surveillance versus radical treatment for favorable-risk localized prostate cancer. Curr Treat Options Oncol (2006) 1.06
Prostate cryoablation using direct transperineal placement of ultrathin probes through a 17-gauge brachytherapy template-technique and preliminary results. Urology (2001) 1.05
Dosimetric comparison of three different involved nodal irradiation techniques for stage II Hodgkin's lymphoma patients: conventional radiotherapy, intensity-modulated radiotherapy, and three-dimensional proton radiotherapy. Int J Radiat Oncol Biol Phys (2009) 1.05
Cold atmospheric plasma, a new strategy to induce senescence in melanoma cells. Exp Dermatol (2013) 1.04
Development and Evaluation of an Actuated MRI-Compatible Robotic System for MRI-Guided Prostate Intervention. IEEE ASME Trans Mechatron (2011) 1.03
Imaging in prostate cancer diagnosis: present role and future perspectives. Urol Int (2011) 1.02
Atmospheric pressure plasma: a high-performance tool for the efficient removal of biofilms. PLoS One (2012) 1.01
Functional magnetic resonance imaging in prostate cancer. Eur Urol (2009) 1.01
Focal therapy in prostate cancer: modalities, findings and future considerations. Nat Rev Urol (2010) 1.00
Inactivation of Salmonella enterica serovar Typhimurium on fresh produce by cold atmospheric gas plasma technology. Food Microbiol (2012) 0.99
Acute toxicity after cyberknife-delivered hypofractionated radiotherapy for treatment of prostate cancer. Am J Clin Oncol (2011) 0.99
Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience. Oncol Rep (2008) 0.98
Active surveillance: patient selection. Curr Opin Urol (2013) 0.98
Focal therapy for prostate cancer: possibilities and limitations. Eur Urol (2010) 0.97
Porcine intact and wounded skin responses to atmospheric nonthermal plasma. J Surg Res (2012) 0.96
Cold plasma is well-tolerated and does not disturb skin barrier or reduce skin moisture. J Dtsch Dermatol Ges (2012) 0.95
Singlet oxygen-induced signaling effects in mammalian cells. Photochem Photobiol Sci (2003) 0.95
Ultrasound of the prostate. Cancer Imaging (2010) 0.94
MR imaging-guided focal cryoablation in patients with recurrent prostate cancer. Radiology (2013) 0.93
Eradication of Pseudomonas aeruginosa biofilms by atmospheric pressure non-thermal plasma. PLoS One (2012) 0.93
Clinical application of argon plasma coagulation in gastrointestinal endoscopy: has the time come to replace the laser? Endoscopy (2001) 0.92
A preliminary study of the effect of DBD plasma and osmolytes on T98G brain cancer and HEK non-malignant cells. Molecules (2013) 0.92
Radiotherapy targeting cancer stem cells: current views and future perspectives. Anticancer Res (2013) 0.92
HDAC inhibitor confers radiosensitivity to prostate stem-like cells. Br J Cancer (2013) 0.91
Focal therapy in the management of prostate cancer: an emerging approach for localized prostate cancer. Adv Urol (2012) 0.91
Tissue ablation in benign prostatic hyperplasia with high-intensity focused ultrasound. Eur Urol (1993) 0.91
Focal therapy: a new paradigm for the treatment of prostate cancer. Rev Urol (2009) 0.91
MRI-guided interventions for the treatment of prostate cancer. AJR Am J Roentgenol (2012) 0.91
Role of MRI in prostate cancer detection. NMR Biomed (2013) 0.90
Focal therapy of prostate cancer: energies and procedures. Urol Oncol (2012) 0.90
Focal therapy for prostate cancer: rationale and treatment opportunities. Clin Oncol (R Coll Radiol) (2013) 0.89
Peroxynitrite-dependent killing of cancer cells and presentation of released tumor antigens by activated dendritic cells. J Immunol (2010) 0.89
Photodynamic therapy for focal ablation of the prostate. World J Urol (2010) 0.88
Percutaneous MR-guided cryoablation of prostate cancer: initial experience. Eur Radiol (2012) 0.88
Review of primary and salvage cryoablation for prostate cancer. Cancer Control (2007) 0.87